Merck & Co. (MRK) : Chevy Chase Trust Holdings scooped up 130,339 additional shares in Merck & Co. during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Jul 8, 2016. The investment management firm now holds a total of 2,930,529 shares of Merck & Co. which is valued at $173,926,896.Merck & Co. makes up approximately 0.96% of Chevy Chase Trust Holdings’s portfolio.
Other Hedge Funds, Including , Exxonmobil Investment Management Inc Tx boosted its stake in MRK in the latest quarter, The investment management firm added 40,796 additional shares and now holds a total of 716,504 shares of Merck & Co. which is valued at $42,524,512. Merck & Co. makes up approx 0.89% of Exxonmobil Investment Management Inc Tx’s portfolio.Raymond James Trust N.a. boosted its stake in MRK in the latest quarter, The investment management firm added 10,865 additional shares and now holds a total of 337,745 shares of Merck & Co. which is valued at $20,045,166. Merck & Co. makes up approx 1.68% of Raymond James Trust N.a.’s portfolio.Patten Patten Inctn boosted its stake in MRK in the latest quarter, The investment management firm added 986 additional shares and now holds a total of 166,096 shares of Merck & Co. which is valued at $9,857,798. Merck & Co. makes up approx 1.35% of Patten Patten Inctn’s portfolio.Cacti Asset Management reduced its stake in MRK by selling 625 shares or 0.1% in the most recent quarter. The Hedge Fund company now holds 607,594 shares of MRK which is valued at $35,203,996. Merck & Co. makes up approx 3.82% of Cacti Asset Management’s portfolio.
Merck & Co. closed down -0.05 points or -0.08% at $59.55 with 67,93,185 shares getting traded on Wednesday. Post opening the session at $59.78, the shares hit an intraday low of $59.4801 and an intraday high of $59.95 and the price fluctuated in this range throughout the day.Shares ended Wednesday session in Red.
On the company’s financial health, Merck & Co. reported $0.89 EPS for the quarter, beating the analyst consensus estimate by $ 0.04 according to the earnings call on May 5, 2016. Analyst had a consensus of $0.85. The company had revenue of $9312.00 million for the quarter, compared to analysts expectations of $9445.10 million. The company’s revenue was down -1.2 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $0.85 EPS.
Merck & Co. Inc. is a global health care company. The Company offers health solutions through its prescription medicines vaccines biologic therapies and animal health products which it markets directly and through its joint ventures. The Companys Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures. Human health pharmaceutical products consist of therapeutic and preventive agents generally sold by prescription for the treatment of human disorders. The Company sells these human health pharmaceutical products primarily to drug wholesalers and retailers hospitals government agencies and managed health care providers. The Animal Health segment discovers develops manufactures and markets animal health products including vaccines. The Companys animal health products are sold to veterinarians distributors and animal producers.